Evidence map›Paper›PMID 32564144›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2021

Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response.

A Sultan, J Wörmann, J Lüker, J -H V D Bruck, T Plenge, V Rudolph, A Klinke, J Heijman, M Mollenhauer, T Ravekes and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

A Sultan *Department of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany. arian.sultan@uk-koeln.de.
J Wörmann *Department of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-2213-8946
J LükerDepartment of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany.
J -H V D BruckDepartment of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany.
T PlengeDepartment of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany.
V RudolphDepartment of Cardiology, Heart and Diabetes Center North-Rhine Westphalia, Bad Oeynhausen, Germany.
A KlinkeDepartment of Cardiology, Heart and Diabetes Center North-Rhine Westphalia, Bad Oeynhausen, Germany.
J HeijmanDepartment of Cardiology, Maastricht University, Maastricht, The Netherlands.
M MollenhauerDepartment of Cardiology and Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany.
T RavekesDepartment of Cardiology and Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany.
S BaldusDepartment of Cardiology and Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany.
D StevenDepartment of Electrophysiology, Heart Center, University of Cologne, Cologne, Germany.
University of Cologne · DEHeart and Diabetes Center North Rhine-Westphalia · DEMaastricht University · NLTH Köln - University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to determine if changes in myeloperoxidase (MPO) levels correlate with response to cardiac resynchronization therapy (CRT) and the potential role of MPO as a predictor of response to CRT.

backgroundCRT is a well-established treatment option in chronic heart failure (CHF) with 50-80% of patients benefiting. Inflammation and oxidative stress play a key role in CHF pathophysiology. Previous studies have demonstrated increased levels of MPO in CHF patients, but the correlation with CRT response remains incompletely understood.

methodsFifty-three patients underwent CRT implantation. During follow-up, patients were divided into two groups, responders and non-responders to CRT, based on improved physical capacity and NYHA classification. Levels of MPO and NT-pro-brain-natriuretic-peptide (NT-proBNP) were determined prior to implantation, 30 and 90 days after. Physical capacity, including a 6-min walking-test, NYHA class, and LVEF were evaluated at baseline and during follow-up.

resultsThirty-four patients (64%) responded to CRT, showing improved physical capacity and LVEF. All responders revealed a significant decrease of MPO levels (503.8 ng/ml vs. 188.4 ng/ml; p < 0.001). Non-responding patients did not show any significant changes in clinical parameters or MPO levels (119.6 ng/ml vs. 134.3 ng/ml; p = 0.672) during follow-up. At baseline, physical capacity and NYHA class, as well as MPO levels differed significantly between both groups (p < 0.001). A ROC analysis identified an MPO cut-off value for response to CRT of 242 ng/ml with a sensitivity of 93.5% and specificity of 71.4%. There was a strong correlation between MPO and improvement of LVEF (Spearman's rho: - 0.453; p = 0.005) and physical capacity (Spearman's rho: - 0.335; p = 0.042).

conclusionsResponse to CRT and course of MPO levels correlate significantly. MPO levels differ between responders and non-responders prior to CRT, which may indicate an additional value of MPO as a predictor for CRT response. Further randomized studies are required to confirm our data in larger patient cohorts.

Indexed as

Cardiac Resynchronization TherapyAgedBiomarkersFemaleHeart FailureHumansMaleNatriuretic Peptide, BrainPeptide FragmentsPeroxidasePredictive Value of TestsBiomarkersMPO protein, humanNatriuretic Peptide, BrainPeptide FragmentsPeroxidasepro-brain natriuretic peptide (1-76)Cardiac resynchronization therapyInflammationMyeloperoxidaseNon-responseResponse

Identifiers

PMID32564144
PMCPMC8318955
OpenAlexW3036075660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.